AIMS/HYPOTHESIS: An accurate molecular diagnosis of diabetes subtype confers clinical benefits; however, many individuals with monogenic diabetes remain undiagnosed. Biomarkers could help to prioritise patients for genetic investigation. We recently demonstrated that high-sensitivity C-reactive protein (hsCRP) levels are lower in UK patients with hepatocyte nuclear factor 1 alpha (HNF1A)-MODY than in other diabetes subtypes. In this large multi-centre study we aimed to assess the clinical validity of hsCRP as a diagnostic biomarker, examine the genotype-phenotype relationship and compare different hsCRP assays. METHODS: High-sensitivity CRP levels were analysed in individuals with HNF1A-MODY (n = 457), glucokinase (GCK)-MODY (n = 404), hepatocyte nuclear factor 4 alpha (HNF4A)-MODY (n = 54) and type 2 diabetes (n = 582) from seven European centres. Three common assays for hsCRP analysis were evaluated. We excluded 121 participants (8.1%) with hsCRP values >10 mg/l. The discriminative power of hsCRP with respect to diabetes aetiology was assessed by receiver operating characteristic curve-derived C-statistic. RESULTS: In all centres and irrespective of the assay method, meta-analysis confirmed significantly lower hsCRP levels in those with HNF1A-MODY than in those with other aetiologies (z score -21.8, p < 5 × 10(-105)). HNF1A-MODY cases with missense mutations had lower hsCRP levels than those with truncating mutations (0.03 vs 0.08 mg/l, p < 5 × 10(-5)). High-sensitivity CRP values between assays were strongly correlated (r (2) ≥ 0.91, p ≤ 1 × 10(-5)). Across the seven centres, the C-statistic for distinguishing HNF1A-MODY from young adult-onset type 2 diabetes ranged from 0.79 to 0.97, indicating high discriminative accuracy. CONCLUSIONS/ INTERPRETATION: In the largest study to date, we have established that hsCRP is a clinically valid biomarker for HNF1A-MODY in European populations. Given the modest costs and wide availability, hsCRP could translate rapidly into clinical practice, considerably improving diagnosis rates in monogenic diabetes.
AIMS/HYPOTHESIS: An accurate molecular diagnosis of diabetes subtype confers clinical benefits; however, many individuals with monogenic diabetes remain undiagnosed. Biomarkers could help to prioritise patients for genetic investigation. We recently demonstrated that high-sensitivity C-reactive protein (hsCRP) levels are lower in UK patients with hepatocyte nuclear factor 1 alpha (HNF1A)-MODY than in other diabetes subtypes. In this large multi-centre study we aimed to assess the clinical validity of hsCRP as a diagnostic biomarker, examine the genotype-phenotype relationship and compare different hsCRP assays. METHODS: High-sensitivity CRP levels were analysed in individuals with HNF1A-MODY (n = 457), glucokinase (GCK)-MODY (n = 404), hepatocyte nuclear factor 4 alpha (HNF4A)-MODY (n = 54) and type 2 diabetes (n = 582) from seven European centres. Three common assays for hsCRP analysis were evaluated. We excluded 121 participants (8.1%) with hsCRP values >10 mg/l. The discriminative power of hsCRP with respect to diabetes aetiology was assessed by receiver operating characteristic curve-derived C-statistic. RESULTS: In all centres and irrespective of the assay method, meta-analysis confirmed significantly lower hsCRP levels in those with HNF1A-MODY than in those with other aetiologies (z score -21.8, p < 5 × 10(-105)). HNF1A-MODY cases with missense mutations had lower hsCRP levels than those with truncating mutations (0.03 vs 0.08 mg/l, p < 5 × 10(-5)). High-sensitivity CRP values between assays were strongly correlated (r (2) ≥ 0.91, p ≤ 1 × 10(-5)). Across the seven centres, the C-statistic for distinguishing HNF1A-MODY from young adult-onset type 2 diabetes ranged from 0.79 to 0.97, indicating high discriminative accuracy. CONCLUSIONS/ INTERPRETATION: In the largest study to date, we have established that hsCRP is a clinically valid biomarker for HNF1A-MODY in European populations. Given the modest costs and wide availability, hsCRP could translate rapidly into clinical practice, considerably improving diagnosis rates in monogenic diabetes.
Authors: D Q Shih; M Bussen; E Sehayek; M Ananthanarayanan; B L Shneider; F J Suchy; S Shefer; J S Bollileni; F J Gonzalez; J L Breslow; M Stoffel Journal: Nat Genet Date: 2001-04 Impact factor: 38.330
Authors: Ewan R Pearson; Bryan J Starkey; Roy J Powell; Fiona M Gribble; Penny M Clark; Andrew T Hattersley Journal: Lancet Date: 2003-10-18 Impact factor: 79.321
Authors: C C Lee; A I Adler; M S Sandhu; S J Sharp; N G Forouhi; S Erqou; R Luben; S Bingham; K T Khaw; N J Wareham Journal: Diabetologia Date: 2009-03-27 Impact factor: 10.122
Authors: Alexander P Reiner; Mathew J Barber; Yongtao Guan; Paul M Ridker; Leslie A Lange; Daniel I Chasman; Jeremy D Walston; Gregory M Cooper; Nancy S Jenny; Mark J Rieder; J Peter Durda; Joshua D Smith; John Novembre; Russell P Tracy; Jerome I Rotter; Matthew Stephens; Deborah A Nickerson; Ronald M Krauss Journal: Am J Hum Genet Date: 2008-04-24 Impact factor: 11.025
Authors: Paul M Ridker; Guillaume Pare; Alex Parker; Robert Y L Zee; Jacqueline S Danik; Julie E Buring; David Kwiatkowski; Nancy R Cook; Joseph P Miletich; Daniel I Chasman Journal: Am J Hum Genet Date: 2008-04-24 Impact factor: 11.025
Authors: A Stride; M Vaxillaire; T Tuomi; F Barbetti; P R Njølstad; T Hansen; A Costa; I Conget; O Pedersen; O Søvik; R Lorini; L Groop; P Froguel; A T Hattersley Journal: Diabetologia Date: 2002-03 Impact factor: 10.122
Authors: Ewan R Pearson; Sylvia F Boj; Anna M Steele; Timothy Barrett; Karen Stals; Julian P Shield; Sian Ellard; Jorge Ferrer; Andrew T Hattersley Journal: PLoS Med Date: 2007-04 Impact factor: 11.069
Authors: David T Broome; Kevin M Pantalone; Sangeeta R Kashyap; Louis H Philipson Journal: J Clin Endocrinol Metab Date: 2021-01-01 Impact factor: 5.958
Authors: Shideh Majidi; Alexandra Fouts; Laura Pyle; Christina Chambers; Taylor Armstrong; Zhenyuan Wang; Sat Dev Batish; Georgeanna Klingensmith; Andrea K Steck Journal: Diabetes Technol Ther Date: 2018-02 Impact factor: 6.118
Authors: Bas C T van Bussel; Isabel Ferreira; Marjo P H van de Waarenburg; Marleen M J van Greevenbroek; Carla J H van der Kallen; Ronald M A Henry; Edith J M Feskens; Coen D A Stehouwer; Casper G Schalkwijk Journal: PLoS One Date: 2013-03-05 Impact factor: 3.240